Ista is a company I've talked about before. Their primary product is XiBrom for the treatment of ocular pain and inflammation following eye surgery. The product lost exclusivity in January of this year but the company has yet to face any generic competition. The threat of generic competition is a real one, however, as Xibrom makes up over half of the company's revenues. As of the most recent quarter, operating cash flows were virtually zero.
Ista may have a rosier future, however. Total product sales year-over-year have increased 47% from 2009 to 2010. Furthermore, XiDay, a once daily version of Xibrom, faces a PDUFA date of October 16 and could allow Ista to maintain its XiBrom revenues. The company has several other treatments in the pipeline - including ecabet sodium and bromfenac for dry eye and T-Pred for inflammatory ocular conditions - but none have advanced beyond phase II trials yet.
Ista is covered by three research analysts with an average 'buy' rating and an average one year price target of $6.33/share.
News 
Market Data 
Discover 
